CTAD 2024 | Measuring clinically relevant change in apathy symptoms in AD using data from the ADMET trials

Krista Lanctôt, PhD, Sunnybrook Research Institute, University of Toronto, Canada, comments on an analysis of the clinically relevant change in apathy symptoms for patients with Alzheimer’s who were treated in the ADMET (NCT01117181) and ADMET2 (NCT02346201) trials. The analysis calculated minimal clinically important differences (MCIDs) for the Neuropsychiatric Inventory (NPI) apathy subscale score, finding a change of at least four points to be clinically significant. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.